Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Immunogenicity and Safety of 3 Adjuvated Reduced Dose Inactivated Polio Vaccines (IPV-Al SSI) and Non-adjuvated Full Dose IPV SSI, Given as Primary Vaccinations to Infants at 6, 10 and 14 Weeks of Age

NCT02347423 is registered in ClinicalTrials.gov with Statens Serum Institut as lead sponsor.

NCT NCT02347423
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02347423 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Immunogenicity and Safety of 3 Adjuvated Reduced Dose Inactivated Polio Vaccines (IPV-Al SSI) and Non-adjuvated Full Dose IPV SSI, Given as Primary Vaccinations to Infants at 6, 10 and 14 Weeks of Age
Lead sponsor
Statens Serum Institut
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2015
Completion date
September 26, 2015
Enrollment
824 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

poliomyelitis